Stockreport

Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68  Parkinson’s and Alzheimer’s Patients

Annovis Bio, Inc.  (ANVS) 
PDF BERWYN, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Par [Read more]